Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.
Investing.com-- Eli Lilly and Company (NYSE:LLY) said on Tuesday evening that China’s food and drug regulator had approved its Kisunla treatment for early symptomatic Alzheimer's ...
Argus Research analyst Jasper Hellweg maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares ...
**NM signifies a non meaningful value. A dash signifies the data is not available.